UPPSALA, Sweden, May 27, 2004 (PRIMEZONE) -- Q-Med's new product, RESTYLANE Vital, has obtained CE certification for the indication for hydration of the skin by injections. The approval of RESTYLANE Vital means that the product can now be marketed in the European Union, Norway and Switzerland.
RESTYLANE Vital is a new product aimed at skin rejuvenation. RESTYLANE Vital hydrates the skin, improving its elasticity and tone. RESTYLANE Vital will enable Q-Med to broaden its customer base and strengthen the growth within instant esthetic treatments.
"RESTYLANE Vital will be a valuable extension of the RESTYLANE product range and will give the physicians an opportunity to attract consumers, who are looking for a vital and fresh appearance for their skin," says Anna Tenstam Lundvall, Vice President, Esthetics Business Unit.
"RESTYLANE Vital enables us to strengthen and broaden our position as the market leader within instant esthetic treatments," concludes Anna Tenstam Lundvall.
RESTYLANE Vital is based on Q-Med's patented NASHA technology, just like RESTYLANE Touch, RESTYLANE and RESTYLANE Perlane.
Queries should be addressed to: Bengt Agerup, President and CEO Ph: +46 (0) 70 974 90 25 Anna Tenstam Lundvall, Vice President, Esthetics Business Unit, Ph: +46(0) 70 974 90 95
Visit www.restylane.com for more information
Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology -- Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has 480 employees, with approximately 310 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the Attract 40 list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/05/27/20040527BIT20210/wkr0006.pdf